Article

Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Comparison to a Standard 3 T MRI

Haidara Almansour 1, Saif Afat 1, Victor Fritz 2, Fritz Schick 2, Marcel Nachbar 3, Daniela Thorwarth 3,4, Daniel Zips 4,5, Arndt-Christian Müller 5, Konstantin Nikolaou 1, Ahmed E. Othman 1,6,* and Daniel Wegener 5

1 Department of Diagnostic and Interventional Radiology, Eberhard-Karls University, 72076 Tuebingen, Germany; haidara.al-mansour@med.uni-tuebingen.de (H.A.); saif.afat@med.uni-tuebingen.de (S.A.); konstantin.nikolaou@med.uni-tuebingen.de (K.N.)
2 Section for Experimental Radiology, Department of Radiology, Eberhard-Karls University, 72076 Tuebingen, Germany; victor.fritz@med.uni-tuebingen.de (V.F.); fritz.schick@med.uni-tuebingen.de (F.S.)
3 Section for Biomedical Physics, Department of Radiation Oncology, Eberhard-Karls University, 72076 Tuebingen, Germany; marcel.nachbar@med.uni-tuebingen.de (M.N.); daniela.thorwarth@med.uni-tuebingen.de (D.T.)
4 German Cancer Consortium (DKTK), Partner Site Tuebingen and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; daniel.zips@med.uni-tuebingen.de
5 Department of Radiation Oncology, Eberhard-Karls University, 72076 Tuebingen, Germany; arndt-christian.mueller@med.uni-tuebingen.de (A.-C.M.); Daniel.wegener@med.uni-tuebingen.de (D.W.)
6 Department of Neuroradiology, University Medical Center Mainz, 55131 Mainz, Germany
* Correspondence: ahmed.othman@med.uni-tuebingen.de

Simple Summary: High-precision MR-guided radiotherapy (MRgRT) constitutes the state-of-the-art in the sphere of personalized prostate cancer treatment. To this end, integrating a 1.5 T scanner with a linear accelerator led to the development of MR-Linac (MRL), which could be considered a novel deflection point in radiation oncology. Since the success of both diagnosis and radiation treatment is highly dependent on image quality, geometric integrity, and lesion conspicuity, it is important to investigate the quality of these sequences in comparison to the current diagnostic gold standard multiparametric MRI at 3T (MRI3T), which has not been done before. The purpose of this study is to conduct a qualitative and a quantitative analysis of MRL-images at 1.5 T in patients undergoing MRgRT planning for prostate cancer. Results from this study pave the way for developing safer and more efficient planning workflows in patients with prostate cancer undergoing MR-guided radiotherapy.

Abstract: The objective of this study is to conduct a qualitative and a quantitative image quality and lesion evaluation in patients undergoing MR-guided radiation therapy (MRgRT) for prostate cancer on a hybrid magnetic resonance imaging and linear accelerator system (MR-Linac or MRL) at 1.5 Tesla. This prospective study was approved by the institutional review board. A total of 13 consecutive patients with biopsy-confirmed prostate cancer and an indication for MRgRT were included. Prior to radiation therapy, each patient underwent an MR-examination on an MRL and on a standard MRI scanner at 3 Tesla (MRI3T). Three readers (two radiologists and a radiation oncologist) conducted an independent qualitative and quantitative analysis of T2-weighted and diffusion-weighted images (DWI). Qualitative outcome measures were as follows: zonal anatomy, capsule demarcation, resolution, visibility of the seminal vesicles, geometric distortion, artifacts, overall image quality, lesion conspicuity, and diagnostic confidence. All ratings were performed on an ordinal 4-point Likert scale. Lesion conspicuity and diagnostic confidence were firstly analyzed only on MRL. Afterwards, these outcome parameters were analyzed in consensus with the MRI3T. Quantitative outcome measures were as follows: anteroposterior and right left diameter of the prostate, lesion size, PI-RADS score (Prostate Imaging—Reporting and Data System) and apparent diffusion coefficient (ADC) of the lesions. Intergroup comparisons were computed using the Wilcoxon-sign
rank test and t tests. A post-hoc regression analysis was computed for lesion evaluation. Finally, inter-/intra-reader agreement was analyzed using the Fleiss kappa and intraclass correlation coefficient. For T2w images, the MRL showed good results across all quality criteria (median 3 and 4). Furthermore, there were no significant differences between MRL and MRI3T regarding capsule demarcation or geometric distortion. For the DWI, the MRL performed significantly less than MRI3T across most image quality criteria with a median ranging between 2 and 3. However, there were no significant differences between MRL and MRI3T regarding geometric distortion. In terms of lesion conspicuity and diagnostic confidence, inter-reader agreement was fair for MRL alone (Kappa = 0.42) and good for MRL in consensus with MRI3T (Kappa = 0.708). Thus, lesion conspicuity and diagnostic confidence could be significantly improved when reading MRL images in consensus with MRI3T (Odds ratio: 9- to 11-fold for the T2w images and 5- to 8–fold for the DWI) \((p < 0.001)\). For measures of lesion size, anterior-posterior and right-left prostate diameter, inter-reader and intersequence agreement were excellent (ICC > 0.90) and there were no significant differences between MRL and MRI3T among all three readers. In terms of Prostate Imaging Reporting and Data System (PIRADS) scoring, no significant differences were observed between MRL and MRI3T. Finally, there was a significant positive linear relationship between lesion ADC measurements \((r = 0.76, p < 0.01)\) between the ADC values measured on both systems. In conclusion, image quality for T2w was comparable and diagnostic even without administration of spasmolytic- or contrast agents, while DWI images did not reach diagnostic level and need to be optimized for further exploitation in the setting of MRgRT. Diagnostic confidence and lesion conspicuity were significantly improved by reading MRL in consensus with MRI3T which would be advisable for a safe planning and treatment workflow. Finally, ADC measurements of lesions on both systems were comparable indicating that, lesion ADC as measured on the MRL could be used as a biomarker for evaluation of treatment response, similar to examinations using MRI3T.

**Keywords:** prostate carcinoma; mpMRI; adaptive radiotherapy; image guidance; MR-Linac; PIRADS; image quality; lesion detection

1. Introduction

Magnetic resonance imaging (MRI) constitutes the cornerstone in the diagnosis and staging of prostate cancer as it has an indispensable role in the clinical routine due to its exquisite delineation of prostate and pelvic anatomy \([1,2]\). Recent technological developments have expanded the role of MRI and revolutionized personalized prostate cancer treatment via high-precision MR-guided radiotherapy (MRgRT). To this end, integrating a 1.5 T scanner with a linear accelerator led to the development of MR-Linac (MRL), which can be considered a novel deflection point in radiation oncology \([3,4]\). This integration builds on the idea that safe radiation therapy is predicated on well focused tumor treatment without markedly injuring the neighboring healthy tissues, since therapeutic radiation doses required to destroy cancerous lesions mostly exceed the tolerable threshold by healthy tissues \([5]\).

On the MRI table, the novel MRL system enables a continuous “real-time” or “online” visualization of the prostate and neighboring organs with high soft-tissue contrast and allows for real-time plan adaptation and dynamic decision-making. The MRL T2-weighted (T2w) sequence of the MRL used for daily plan adaptation requires acquisition time of less than two minutes. Furthermore, the 1.5T MRL enables real-time functional imaging like diffusion-weighted-imaging (DWI) for response assessment and biological radiation adaptation. Since the success of both diagnosis and radiation treatment is highly dependent on image quality, geometric integrity and lesion conspicuity, it is important to investigate the quality of these sequences in comparison to the current diagnostic gold standard which is multiparametric MRI at 3T (MRI3T) \([6]\).
Currently, MRI3T serves as a diagnostic standard of reference for the images that are recorded on MR-Linac. Using the images recorded on MRI3T aids physicians in radiation treatment planning, lesion segmentation as well as segmentation of the neighboring organs to protect the organs at risk (OAR).

The purpose of this study is to conduct a qualitative and a quantitative analysis of T2w and DW-images recorded on MRL at 1.5 T in patients undergoing MRgRT planning for prostate cancer using MRI3T as a standard of reference.

2. Materials and Methods

2.1. Study Design and Patient Population

This prospective single-center study was approved by the institutional review board. All patients participated in the M-base Pro 1.0 or M-base HyPro 2.0 studies for primary radiation therapy of localized prostate cancers at our clinic for radiation oncology (ClinicalTrials.gov Identifiers: NCT02724670; NCT03880851). Within those studies, all patients consented in writing to undergo a second MRI examination at 3T. Between February 2019 and June 2020, a total of 13 consecutive patients with biopsy-confirmed prostate cancer and complete MRL and MRI3T data sets were included.

2.2. MRI Technique and Acquisition Parameters

2.2.1. MRI Examination at MRL

Peristalsis was not suppressed prior to the MRI examination and no contrast medium was administered. All examinations were performed in supine position in the hybrid 1.5 T MRI scanner (Elekta Unity™, Philips, Stockholm, Sweden), which is a modified 1.5T Philips Ingenia (Best, The Netherlands). An 8-channel body array coil was utilized for signal reception. The coil is designed to have minimal attenuation of the radiation beam by placing 4 channels anterior to the patient and 4 channels posterior to the patient. The posterior coil is embedded in the patient couch, while the anterior coil rests on a holder which prevents contact to the patient’s body [7]. No endorectal coils were applied. All patients underwent an MRgRT planning protocol consisting of axial T2w imaging in the axial plane and DWI using three different b-values (50 s/mm², 500 s/mm², and 800 s/mm²) followed by reconstruction of apparent diffusion coefficient (ADC) maps.

2.2.2. MRI Examinations at 3T

Prior to the MRI examination, peristalsis was suppressed by the IV administration of 20 mg of butyl scopolamine (Buscopan, Boehringer, Germany). Body-weight adapted contrast agent was administered (0.1 mmol/kg gadobutrol; Gadovist, Bayer Healthcare, Leverkusen, Germany) with a flow rate of 1.5 mL/s followed by a saline flush of 20 mL using a power injector. All examinations were performed in supine position using a clinical 3T MRI scanner (MAGNETOM Skyra, Siemens Healthcare, Erlangen, Germany). A combined coil setup of an 18-channel body coil and 12 elements of a 32-channel spine coil was utilized. No endorectal coils were used. All included patients underwent a routine multi parametric (mpMRI) consisting of T2w imaging in three dimensions angulated to the prostate, as well as DWI using three different b-values (50 s/mm², 500 s/mm², 1000 s/mm² and a calculated 2000 s/mm²) with reconstruction of ADC maps. ADC-maps were generated and analyzed offline using an in-house developed program based on MATLAB software (MATLAB; MathWorks, Natick, MA, USA) (Source Code S1). A standard log-linear model was applied to calculate ADC-values voxel-wise in each slice and for each patient for MRL and MRI3T. The acquisition parameters used for MRL and MRI3T imaging are given in Table 1.
Table 1. Magnetic Resonance Acquisition Parameters of T2-weighted images and DWI for MRL and MRI3T.

| Parameter                      | MR-Linac       | MRI3T          |
|--------------------------------|----------------|----------------|
|                                | 3D T2          | DWI-SPAIR      | T2—TSE   | DWI         |
| Field of view (mm)             | 400 × 400      | 430 × 430      | 200 × 200 | 256 × 192   |
| Acquisition voxel size (mm³)   | 1.5 × 1.5 × 2  | 3 × 3 × 4.5    | 0.65 × 0.52 × 3 | 1.67 × 1.33 × 4 |
| Repetition time (msec)         | 1535           | 8907           | 4000–8000 | 5930        |
| Echo time (msec)               | 278            | 77             | 90        | 76          |
| Refocusing flip angle (degrees)| 100            | 180            | 120       | 180         |
| Section thickness (mm)         | 2              | 4.5            | 3         | 4           |
| Time for acquisition (min:sec) | 01:57          | 05:30          | 3:40–5:00 | 5:00–06:00 |
| Bandwidth                      | 740.3 Hz/Pixel | 1902 Hz/Pixel  | 200 Hz/Pixel | 1976 Hz/Pixel |

3D: three-dimensional; T2 = T2-weighted; TSE: turbo spin echo; DWI: Diffusion-weighted Imaging; SPAIR: Spectral attenuated inversion recovery.

2.3. MR-Image Evaluation

In each patient, T2-weighted, DWI images, and ADC maps from examinations on MRL and MRI3T were independently presented to three readers in a random order (reader 1, a radiation oncologist with 6 years of experience in radiation oncology, reader 2, a radiologist with 3 years of experience in interpreting prostate MRI, reader 3, a radiologist with 6 years of experience in interpreting prostate MRI). In addition, dynamic contrast enhanced (DCE) images for MRI3T were reviewed. A dedicated workstation (GE Healthcare Centricity™ PACS RA1000, Milwaukee, WI, USA) was utilized for image analysis.

2.3.1. Qualitative Image Analysis

Qualitative ratings were performed on an ordinal 4-point Likert scale with 4 being the best: (1 = non-diagnostic; 2 = poor; 3 = good; 4 = excellent). “Zonal anatomy”: the ability to differentiate peripheral zone (PZ) from transition zone (TZ). “Resolution”: the ability to identify anatomical details within the prostate. “Capsule demarcation”: the ability to continuously identify the prostatic capsule. Overall image quality (1 = non-diagnostic; 2 = poor image quality, which merits the repetition of MRI examination; 3 = good image quality; 4 = excellent image quality). Diagnostic confidence (1 = non-diagnostic; 2 = poor confidence which merits the repetition of MRI examination; 3 = good confidence; 4 = very good confidence). Lesion conspicuity was subjectively rated as follows: (1 = delineation of lesion margins is not possible 2 = lesion margins are recognizable but blurry; 3 = good delineation of lesion margins good recognizable; 4 = excellent delineation of lesion margins) [8].

Geometric distortion and artifacts (wrapping, ghosting, susceptibility etc.) were rated separately as follows: Geometric distortion (1 = severe distortion 2 = moderate distortion; 3 = low distortion, 4 = no visible distortion). Artifacts (1 = abundant artifacts leading to image degradation; 2 = severe impediment of image quality by artifacts; 3 = slight impediment of image quality by artifacts, 4 = no visible artifacts).

2.3.2. Quantitative Image Analysis

After qualitative image analysis, the three readers measured the size of the prostatic lesions on T2w and DW sequences in MRL and MRI3T image sets. In addition, the Prostate Imaging Reporting and Data System (PIRADS) score for T2 and DWI image datasets for MRL and MRI3T were evaluated. For assessment of representative ADC values, an elliptic region-of-interest (ROI) was placed by one reader within the lesions for each patient in MRL and MRI3T image sets [9].

Geometric distortion, diameters in the anteroposterior (AP) and left-right (LR) diameter of the prostate were assessed on the level of the verumontanum on axial image sets of both MRL and MRI3T, respectively. The T2w images of MRI3T served as the standard of
reference regarding prostatic anatomic margins. Geometric distortion was defined as the differences in diameters between T2w on MRI3T and DWI on MRL [9].

2.3.3. Lesion Analysis on MRL with and without MRI3T

Lesion conspicuity and diagnostic confidence were first analyzed on MRL images only. Afterwards, these outcome parameters were analyzed again on the MRL images side by side in consensus with images recorded on the MRI3T. Differences between MRL ratings regarding the aforementioned outcome parameters were then computed.

2.4. Statistical Analysis

Continuous variables were reported as mean and standard deviation or median and interquartile range according to data distribution. The Wilcoxon-signed rank test and paired t-test were used for intersequence comparisons. A post-hoc logistic regression analysis (generalized linear model for ordinal valuables) [10,11] was computed for lesion evaluation. Pearson correlation coefficient was used to test the correlation of ADC measurements between MRL and MRI3T. Fleiss Kappa was used to evaluate inter-reader agreement of categorical variables. Values from 0.0 to 0.2 indicate slight agreement, 0.21 to 0.40 fair agreement, 0.41 to 0.60 moderate agreement, 0.61 to 0.80 substantial agreement, and values ranging from 0.81 to 1.0 indicate almost perfect or perfect agreement [12]. Intraclass correlation coefficient (ICC) was used to compute inter-reader agreement for continuous variables. An ICC of less than 0.4 indicates poor agreement, of 0.40 to 0.59 fair agreement, of 0.60 to 0.74 good agreement, and an ICC of 0.75 to 1.00 indicates excellent agreement [13]. Bland–Altman plots were utilized to compare intra-rater agreement of prostate lesion size measurements for each reader. Level of significance was set at 0.05. Statistical analyses were performed using SPSS (v26.0, IBM-Corp, Armonk, NY, USA).

3. Results

A total of 13 males aged 69 ± 7 years with biopsy-confirmed prostate cancer were included. Patient characteristics are given in Table 2. All imaging studies were successfully performed and evaluated. Figures 1–3 are illustrations of T2w and DWI sequences as well as ADC maps for three patients derived from examinations on MRL and MRI3T.

Table 2. Characteristics of the included patients.

| Characteristics                        | Values (mean ± SD, (range))          |
|----------------------------------------|--------------------------------------|
| Age (years)                            | 69 ± 7 (59–79)                       |
| Prostate-specific antigen (ng/mL)      | 8.95 ± 4.95 (2.28–20.60)             |
| Prostate volume (cm³)                  | 40.8 ± 20.6 (14–83)                  |
| Gleason score                          | Number of MRI examinations (n = 13)  |
| • 6                                     | 4                                    |
| • 7a                                    | 5                                    |
| • 7b                                    | 3                                    |
| • 8                                     | 1                                    |
| Prostate cancer stage                  | Number of MRI examinations (n = 13)  |
| • c T2a                                 | 3                                    |
| • c T2b                                 | 2                                    |
| • c T2c                                 | 8                                    |
| Patients who underwent androgen suppression therapy | 7/13 |

SD = standard deviation.
Figure 1. 60-year-old man with prostate-specific antigen level of 2.28 ng/mL and biopsy-confirmed prostate cancer. Axial T2-weighted images, diffusion-weighted images (DWI) and apparent diffusion coefficient (ADC) maps acquired with MR-Linac (MRL) operating at 1.5 T and corresponding images acquired on a standard 3T MRI (MRI3T). Note the hypointense region in the apical aspect of the right peripheral zone (arrows). Images generated with the MRI3T have higher overall image quality, especially in the DWI. Histology of specimen yielded stage cT2a tumor.
Figure 2. 73-year-old man with an initial prostate-specific antigen level of 7.30 ng/mL and biopsy Scheme 2. weighted images, diffusion-weighted images (DWI) and apparent diffusion coefficient (ADC) maps acquired by the MR-Linac (MRL) at 1.5 T and corresponding images from standard MRI at 3T (MRI3T). The left and middle column show MRL and MRI3T images after 3 months of androgenic suppression therapy. The right column illustrates MRI3T images before initiation of androgenic suppression therapy. Note that the lesion in the DWI before initiation of hormone therapy is slightly hyper-intense (arrow), whereas after hormonal therapy, the lesion appears rather iso-intense on DWI. Note the hypo-intense region in the apical posterior-medial aspect of the left peripheral zone (arrows). Again, images generated with the MRI3T have better overall image quality when compared to MRL especially in the DWI. Histology of specimen yielded stage cT2c tumor.
Figure 3. Illustration of T2-weighted axial (first row), coronal (second row) and sagittal (third row) images acquired using MR-Linac (MRL) at 1.5 T and corresponding images recorded on a standard MRI at 3 T (MRI3T) of the same 73-year-old male as in Figure 2. Diffusion-weighted images (DWI) and apparent diffusion coefficient (ADC) maps are depicted. The cancerous lesion on the apical posterior-medial aspect of the left peripheral zone is shown on the axial and sagittal images (arrows).
3.1. Qualitative Image Analysis

3.1.1. Image Quality

Inter-reader agreement for image quality parameters was good (according to the given grading) for both, MRL (Kappa = 0.610) and MRI3T (Kappa = 0.721). Detailed results for the three readers are given in Table 3. In summary, the MRL showed good results for the T2w across all image quality criteria (median 3 and 4), however significantly inferior to the MRI3T. Furthermore, there were no significant differences between MRL and MRI3T regarding capsule demarcation or geometric distortion. For the DWI, the MRL performed significantly less than MRI3T across most image quality criteria with a median ranging between 2 and 3. Finally, there were no significant differences between MRL and MRI3T regarding geometric distortion.

Table 3. Comparison of qualitative image criteria between MR-Linac (MRL) and standard MRI at 3T (MRI3T) for T2w and DWI sequences.

| Outcome Parameters | T2wMRL  | T2w MRI3T | p Value * | DWIMRL | DWI MRI3T | p Value * |
|--------------------|---------|-----------|-----------|--------|-----------|-----------|
| Zonal anatomy      | Reader 1| Reader 1  | Reader 1  | Reader 2| Reader 2  | Reader 2  |
|                    | 3 (0)   | 4 (0)     | 0.002     | 2 (1)  | 4 (1)     | 0.003     |
|                    | 3 (1)   | 4 (0)     | 0.001     | 2 (0)  | 4 (0)     | 0.001     |
|                    | 3 (0)   | 4 (0)     | 0.001     | 2 (0)  | 4 (0)     | 0.001     |
| Resolution         | Reader 1| Reader 1  | Reader 1  | Reader 2| Reader 2  | Reader 2  |
|                    | 3 (0)   | 4 (0)     | 0.003     | 2 (0)  | 4 (0)     | 0.001     |
|                    | 3 (1)   | 4 (0)     | 0.001     | 2 (0)  | 4 (0)     | 0.001     |
|                    | 4 (0)   | 4 (0)     | 0.015     | 3 (1)  | 4 (1)     | 0.01      |
|                    | 4 (0)   | 4 (0)     | 0.317     | 3 (1)  | 4 (1)     | 0.002     |
|                    | 4 (1)   | 4 (0)     | 0.083     | 3 (1)  | 4 (1)     | 0.004     |
| Capsule demarcation| Reader 1| Reader 1  | Reader 1  | Reader 2| Reader 2  | Reader 2  |
|                    | 4 (1)   | 4 (0)     | 0.083     | 2 (1)  | 4 (0)     | 0.002     |
| Visibility of seminal vesicles | Reader 1| Reader 1  | Reader 1  | Reader 2| Reader 2  | Reader 2  |
|                    | 3 (1)   | 4 (0)     | 0.001     | 2 (1)  | 4 (0)     | 0.001     |
|                    | 3 (0)   | 4 (0)     | <0.001    | 3 (1)  | 4 (0)     | 0.001     |
| Artifacts          | Reader 1| Reader 1  | Reader 1  | Reader 2| Reader 2  | Reader 2  |
|                    | 3 (0)   | 4 (0)     | 0.001     | 3 (1)  | 4 (0)     | 0.004     |
|                    | 3 (1)   | 4 (0)     | 0.001     | 3 (1)  | 4 (0)     | 0.004     |
|                    | 3 (0)   | 4 (0)     | <0.001    | 3 (1)  | 4 (0)     | 0.001     |
| Geometric distortion| Reader 1| Reader 1  | Reader 1  | Reader 2| Reader 2  | Reader 2  |
|                    | 4 (1)   | 4 (0)     | 0.015     | 2 (1)  | 4 (0)     | 0.002     |
|                    | 4 (0)   | 4 (0)     | 0.157     | 4 (0)  | 4 (0)     | 0.157     |
|                    | 4 (1)   | 4 (1)     | 0.655     | 4 (0)  | 4 (0)     | 0.083     |
| Overall image quality| Reader 1| Reader 1  | Reader 1  | Reader 2| Reader 2  | Reader 2  |
|                    | 3 (0)   | 4 (0)     | <0.001    | 2 (1)  | 4 (0)     | 0.002     |
|                    | 3 (0)   | 4 (0)     | <0.001    | 2 (1)  | 4 (0)     | 0.002     |

Data is given as median (Interquartile range); MRL: MR-Linac; MRI3T: Standard MRI at 3 Tesla. T2w = T2-weighted; DWI: Diffusion-weighted Imaging. * Bold denotes statistical significance.

3.1.2. Lesion Conspicuity and Diagnostic Confidence on MRL Alone and in Consensus with MRI3T

Inter-reader agreement for lesion conspicuity and diagnostic confidence was fair for MRL alone (Kappa = 0.42) and good for MRL in consensus with MRI3T (Kappa = 0.708). Detailed results for the three readers are given in Table 4. For MRL alone, lesion conspicuity and diagnostic confidence were good in T2w (median 3) but poor in DWI (median 1 to 2). There was a significant improvement in lesion conspicuity and diagnostic confidence when MRL images were viewed in consensus with MRI3T (Very good, median 4 in T2W and good, median 3 in DWI) (Table 4). Furthermore, a post-hoc logistic regression analysis (generalized linear model for ordinal valuables) [10,11] was computed to investigate whether reading MRL images in consensus with MRI3T played a role in improving lesion conspicuity and diagnostic confidence. For every 1-point increase in lesion conspicuity, the estimated odds ratio revealed a positive relation with “MRL with MRI3T” of nearly 9-
fold for the T2w images and of nearly 8-fold for the DWI in comparison to “MRL without MRI3T” ($p < 0.001$) (Table 5).

For every 1-point increase in diagnostic confidence, the estimated odds ratio revealed a positive relation with “MRL with MRI3T” of nearly 11-fold for the T2w images and of nearly 5-fold for the DWI in comparison to “MRL without MRI3T” ($p < 0.001$) (Table 5).

Table 4. Comparison of lesion conspicuity and diagnostic confidence on MR-Linac (MRL) alone and on MRL in consensus with the MRI3T (MRL with MRI3T).

| Outcome Parameters | T2wMRL Reader 1 | T2wMRL Reader 2 | T2wMRL with T2wMRI-3T Reader 1 | T2wMRL with T2wMRI-3T Reader 2 | p Value | DWIMRL Reader 1 | DWIMRL with DWIMRI-3T Reader 1 | DWIMRL with DWIMRI-3T Reader 2 | p Value |
|-------------------|-----------------|-----------------|-------------------------------|-------------------------------|--------|-----------------|-------------------------------|-------------------------------|--------|
| Reader 1          | 3 (1)           | 4 (1)           | 0.014                         | 2 (3)                         | Reader 1 | 3 (2)           | Reader 1 | 3 (1)           | Reader 2 | 0.023 |
| Reader 2          | 3 (1)           | 3 (1)           | 0.004                         | 1 (1)                         | Reader 2 | 3 (1)           | Reader 2 | 0.004           | Reader 2 | 0.006 |
| Reader 3          | 3 (1)           | 4 (1)           | 0.005                         | 2 (1)                         | Reader 3 | 3 (1)           | Reader 3 | 0.004           | Reader 3 | 0.003 |

Data is given as median (Interquartile range); MRL: MR-Linac; MRI3T: Standard MRI at 3 Tesla. T2w = T2-weighted; DWI: Diffusion-weighted Imaging. * Bold denotes statistical significance.

Table 5. Post-hoc logistic regression results for lesion conspicuity and diagnostic confidence in terms of reading the MRL images without MRI3T or in consensus with MRI3T.

| Outcome Parameters | Likelihood Ratio-Chi-Square | Estimate (B) | SE | Wald-Chi-Square | $p$ Value | Odds Ratio | Exp(B) | 95%CI          |
|--------------------|-----------------------------|--------------|----|-----------------|-----------|------------|--------|----------------|
| Lesion conspicuity | T2w                         | 22.271       | 2.197 | 0.516           | 18.117    | $p < 0.001$ | 8.997  | (3.272–24.742) |
| Lesion conspicuity | DWI                         | 25.528       | 2.063 | 0.475           | 18.836    | $p < 0.001$ | 7.870  | (3.1–19.98)    |
| Diagnostic confidence | T2w                       | 26.987       | 2.445 | 0.522           | 21.935    | $p < 0.001$ | 11.527 | (4.144–32.065) |
| Diagnostic confidence | DWI                       | 16.379       | 1.617 | 0.453           | 12.728    | $p < 0.001$ | 5.036  | (2.072–12.239) |

T2w: T2-weighted; DWI: Diffusion-weighted imaging; B: Regression co-efficient; SE: Standard error; CI: Confidence Interval; Exp(B): odds ratio based on the exponentiation of the B coefficient.

3.2. Quantitative Analysis

3.2.1. Lesion Size, Prostate Diameter and Geometric Distortion

Inter-reader agreement was excellent for lesion size, anterior-posterior and right-left prostate diameter (ICC > 0.92). Intersequence agreement (between MRL and MRI3T) for each reader was also excellent. There were no significant differences between MRL and MRI3T regrading lesion size, anterior-posterior and right-left prostate diameters among all three readers (all $p > 0.05$). Details are given in Table 6. In terms of geometric distortion, for all three readers, there was no statistically significant difference between DWI images on MRL in comparison to T2w on MRI3T (all $p > 0.05$) with the highest geometric distortion being 1.7 mm.
Table 6. Comparison of lesion size measurement as well as prostate diameter measurements on T2w- and DWI between MRL and as well intersequence agreement between MRL and MRI3T for each reader.

| Reader 1 | T2w-MRL | T2w-MRI-3T | p Value | ICC * | DWI-MRL | DWI-MRI-3T | p Value | ICC * |
|----------|----------|------------|---------|-------|---------|-----------|---------|-------|
| Lesion size (mm) | 13.4 ± 4.7 | 13.2 ± 4.6 | 0.48 | 0.98 | 13.5 ± 4.6 | 13 ± 4.8 | 0.13 | 0.98 |
| AP Diameter | 36 ± 8.4 | 35.8 ± 8.4 | 0.61 | 0.99 | 35.9 ± 8.5 | 35.2 ± 9.1 | 0.25 | 0.98 |
| RL Diameter | 46.7 ± 6.6 | 46.6 ± 7.2 | 0.85 | 0.98 | 47.9 ± 7.2 | 46.1 ± 8.6 | 0.17 | 0.91 |

Reader 2

| Reader 2 | Lesion size (mm) | 13 ± 5.1 | 12.7 ± 4.9 | 0.41 | 0.98 | 12.9 ± 5.2 | 13 ± 4.9 | 0.65 | 0.98 |
| AP Diameter | 35.7 ± 7.9 | 35.8 ± 7.2 | 0.84 | 0.99 | 36.08 ± 7.9 | 36 ± 9.1 | 0.85 | 0.99 |
| RL Diameter | 46.3 ± 6.6 | 46.5 ± 7.3 | 0.78 | 0.98 | 47.9 ± 7.1 | 46.7 ± 8.1 | 0.33 | 0.92 |

Reader 3

| Reader 3 | Lesion size (mm) | 13.1 ± 4.2 | 13.4 ± 5.1 | 0.55 | 0.95 | 12.8 ± 5.2 | 13 ± 4.9 | 0.65 | 0.98 |
| AP Diameter | 36.1 ± 8.5 | 36 ± 8.5 | 0.73 | 0.99 | 35.9 ± 8.9 | 36.08 ± 8.9 | 0.74 | 0.99 |
| RL Diameter | 46.3 ± 6.4 | 46.2 ± 7.1 | 0.72 | 0.98 | 47.9 ± 7.7 | 46.6 ± 8.7 | 0.31 | 0.91 |

Data is given as mean ± standard deviation. * ICC: Intraclass correlation coefficient refers to intersequence agreement for each reader. AP: anterior-posterior; RL: right-left; ADC: apparent diffusion coefficient; PZ: peripheral zone; TZ: transition zone; MRL: MR-Linac; MRI-3T: standard MRI at 3 Tesla; T2: T2-weighted; DWI: Diffusion-weighted imaging.

3.2.2. PIRADS Scoring

Inter-reader agreement was substantial for both T2w (kappa = 0.803) and DWI (kappa = 0.770). The intersequence agreement ranged from (Kappa of 0.65 to 1) (Table 7). There were no significant differences regarding PIRADS scoring on T2 or DWI between MRL and MRI3T.

Table 7. Comparison of T2w- and DWI- PIRADS score between MR L and MRI3T for each reader as well intersequence agreement between MRL and MRI3T for each reader.

| PIRADS | Reader 1 | Reader 2 | Reader 3 |
|--------|----------|----------|----------|
| T2-Score | T2MRL | T2MRI-3T | T2MRL | T2MRI-3T | T2MRL | T2MRI-3T |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | 1 | 1 | 1 | 1 | 0 | 0 |
| 4 | 7 | 7 | 8 | 9 | 8 | 8 |
| 5 | 5 | 5 | 4 | 4 | 5 | 5 |
| p value | 1 | 0.317 | 1 |
| Inter-sequence agreement | 1 | 0.840 | 1 |
| DWI-Score | DWIMRL | DWIMRI-3T | DWIMRL | DWIMRI-3T | DWIMRL | DWIMRI-3T |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 2 | 1 | 2 | 1 | 2 | 1 |
| 3 | 1 | 2 | 1 | 1 | 1 | 2 |
| 4 | 6 | 5 | 7 | 6 | 4 | 5 |
| 5 | 4 | 5 | 3 | 5 | 6 | 5 |
| p value | 0.157 | 0.102 | 1 |
| Inter-sequence agreement | 0.774 | 0.64 | 0.774 |

PIRADS: Prostate Imaging Reporting and Data System; MRL:MR-Linac; MRI-3T: standard MRI at 3 Tesla; T2w: T2-weighted; DWI: Diffusion-weighted imaging.

3.2.3. Lesion ADC Measurements

For MRL, the mean ADC values showed a slightly higher trend with a mean of $1.07 \times 10^{-3}$ mm$^2$/s ± $0.4 \times 10^{-3}$ mm$^2$/s. For MRI3T, the mean ADC value was $0.8 \times 10^{-3}$ mm$^2$/s ± $0.2 \times 10^{-3}$ mm$^2$/s. There was no statistically significant difference between MRL and MRI3T. Pearson correlation coefficient revealed a positive linear correlation for lesion ADC measurements ($r = 0.76$, $p < 0.01$).
4. Discussion

This prospective study is the first clinical comparison of MR-Linac at 1.5 T to a diagnostic scanner at 3 T in the context of planning MRgRT of prostate cancer. This study shows that comparable quality can be achieved in clinical routine using a fast T2w sequence. Furthermore, we could demonstrate that the weaker magnetic field strength does not significantly compromise PIRADS scoring or lesion size measurements and that the MRL system offers a high geometric integrity. Simultaneously, we showed that functional imaging using DWI needs optimization as it did not reach a high diagnostic level.

The MRL “fast” T2-sequence (with acquisition time less than 2 min) provides sufficient soft tissue contrast for daily plan adaptation and is fine-tuned for speedy and robust image acquisition during radiation treatment as elapsed time is a risk factor for patient motion and organ motion (bladder filling, changes in anorectal filling, and target volume motion) [14,15]. This sequence is the gold standard for daily RT planning on the MRL [14] and used in all “Unity” sites. This allows sharing of data and building of models. As expected the quality of the fast T2w MRL sequence was inferior to a MRI providing high contrast and resolution as well as low motion artifacts. Here, high image quality is further facilitated by the use of contrast agents and spasmolytica (Table 3). Inter-reader reliability was high, further highlighting the good comparability of this modality. In addition, when comparing T2w imaging on MRL with or without addition of the image data from MRI, the logistic regression model revealed a 9-fold increase in diagnostic confidence for the combination. Therefore, it is recommended to combine MRL prostate image viewing and interpretation with results from recent diagnostic MR examinations.

DWI constitutes a fundamental part of mpMRI of the prostate and has shown its value in detecting clinically relevant prostate cancer as well as in assessing cancer aggressiveness [8,16,17]. However, this sequence is challenged by excessive artifacts and geometric distortion as well as susceptibility to B0-field inhomogeneity [8,16,17]. A major goal of a 1.5T MRL is to exploit having access to functional imaging in real-time which would possibly allow real-time response- or toxicity assessment during radiation treatment and subsequent immediate reaction and plan adaptation [18]. Therefore, this sequence is also tuned for short acquisition time and a certain inferiority to a state-of-the art MRI was expected. Neither artefacts nor geometric distortion impeded image quality significantly. This might be explained by the fact that none of the included patients had metallic implants. However, our findings show that the current MRL-DWI images did not reach high diagnostic quality (zonal anatomy 2/4, resolution 2/4, overall image quality 2/4, see Table 3). Using the current settings, lesion conspicuity and diagnostic confidence were not sufficient for reliable interpretation in this cohort according to the three readers. The suboptimal DWI images could be explained by the fact that the MRL-DWI images are currently not being routinely used for treatment planning or plan adaptation. These images were acquired on the first commercial MRL system with a self-made protocol for scientific purposes. The large FoV was deliberately chosen with the aim of allowing response- and toxicity assessment not only of the prostate but of rectal wall and adjacent bladder as well as these being the most relevant and dose-limiting organs at risk. However, this might have contributed to the inferior quality of the DWI for the prostate as size of FoV was demonstrated to influence image quality on 3T scanners [19] and on the MRL [20]. In addition, MpMRI is usually conducted with the aid of spasmolytic agents (i.e., butyl scopolamine), contrast agent and with fine-tuned sequences and specifications while images on the MRL are acquired daily for several weeks along fractionated radiotherapy and the repeated, potentially harmful use of contrast agent or butyl scopolamine is not justified on a daily basis.

DWI on MRL also profited in the linear regression model from consulting the MRI (odds ratio increases for lesion conspicuity of about 8-fold, for diagnostic confidence 5-fold), so that we advise the use of a corresponding MRI as a reference standard.
Using the DWI-derived apparent diffusion coefficient values (ADC) of prostatic lesions as recorded on MRI3T a standard of reference, lesion ADC values on MRL were comparable. This indicates that ADC on MRL may serve as a quantitative prognostic imaging biomarker similarly to MRI3T. Future studies may use ADC on MRL to assess treatment response and to predict clinical outcome. Indeed, this merits an independent prospective examination.

In addition, our data demonstrate low geometric distortion for DWI on the MRL. This is important because geometric integrity is crucial in the setting of radiation treatment. Therefore, MRL sequences need high readout gradient bandwidths at the cost of signal to noise ratio [21]. In comparison with diagnostic MRIs, the latter should also be set for geometric accuracy and should use spatial correction techniques. Both lesion size and AP and RL diameter of the prostate were comparable between modalities as well as readers (Table 6). This finding is in accordance with a phantom MRL study by Wang et al. [7], which showed a distortion of under 0.5 mm and a “first-in-man” study by Raaymakers et al. [22] in four patients with lumbar metastases, showing a distortion of between 0.2 and 0.4 mm. This underlines a good compensation and low impact of both system-specific and patientspecific causes of distortion [23,24] on the MRL images in our cohort.

Previous studies made a comparison between a standard diagnostic 1.5 T and 3 T prostate MRI [2,25]. For instance, Ullrich et al. [25] showed that both field strengths had similar diagnostic performance and PIRADS scoring with an excellent inter-reader agreement for image quality and PIRADS score. In our cohort, PIRADS scoring was similar on MRL and MRI3T with a substantial inter-reader reliability.

The findings of this study should be interpreted within the context of its limitations. First, there is the small patient population who underwent prostate imaging at both devices. It is a fact that the strain associated with a second MRI examination is not well tolerated by all patients, so we included 13 consecutive patients during an 18-month period. Second, acquisition parameters of the MRL were different from the 3T MRI scanner and did not conform to the PIRADS technical recommendations, inherently creating comparison challenges. However, the main purpose of the MRL is to acquire a quick and reliable image for radiation planning and decision-making in real-time and not make the diagnosis of prostate cancer in a suspected lesion. Thirdly, seven out of thirteen-patients in this study had undergone neoadjuvant hormone ablative treatment prior to the examinations. This study deliberately focused on the clinical comparability “regardless” of those technical or oncological differences as that is what clinical routine demands of any two modalities. The endpoints of this study remain relevant in spite of those distinctions.

5. Conclusions

In conclusion, image quality of T2w imaging was comparable and diagnostic even without administration of spasmolytic- or contrast agents, while DWI images did not reach a sufficient diagnostic level and need to be optimized for further exploitation of real-time functional imaging in the setting of MRgRT. Both for T2w and DWI imaging, lesion conspicuity and diagnostic confidence were significantly improved after reading MRL in consensus with MRI3T which would be advisable for a safe planning and treatment workflow. Finally, ADC measurements were comparable, which indicates that lesion ADC as measured on the MRL might be used as a biomarker for evaluation of treatment response, similar to common procedures using MRI3T.

Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/13/7/1533/s1, Source Code S1. Source code for the in-house developed program based on MATLAB software for ADC-mapping.

Author Contributions: Conceptualization, H.A., D.T., A.-C.M., A.E.O. and D.W.; methodology, H.A., V.F., F.S., M.N., D.T., A.-C.M., A.E.O. and D.W.; formal analysis, H.A., V.F., M.N., A.-C.M., A.E.O. and D.W.; resources, D.Z. and K.N.; data curation, H.A., S.A., V.F., M.N., D.W. and A.E.O.; writing—original draft preparation, H.A. and D.W.; writing—review and editing, H.A., S.A., F.S.,
D.T., D.Z., A.-C.M., A.E.O. and D.W.; visualization, H.A.; supervision, D.Z., K.N., A.-C.M. and A.E.O.; funding acquisition, D.T., A.-C.M. and A.E.O. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research project was partially financed through a research grant of the DFG (German Research Council, Grant MU 4603/1-1 OT 534/3-1, Package No. 997/1). The APC was partially funded by the German Research Council (Deutsche Forschungsgemeinschaft) within the funding program Open Access Publishing, by the Baden-Württemberg Ministry of Science, Research and the Arts, and by the Eberhard-Karls-Universität Tübingen.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the medical faculty of Tuebingen University (No. 022/2016BO1, 14 March 2016 and No. 920/2018BO1, 10 July 2019).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**Acknowledgments:** Haidara Almansour is a scholarship recipient of the junior clinician scientist program of the medical faculty of Tuebingen University (no. 461-0-0).

**Conflicts of Interest:** The authors’ institution operates a Linac Unity (Elekta, Sweden). The authors declare no further conflicts of interest. We mention the cooperation with Siemens Healthcare, Philips, Elekta and PTB Braunschweig in another research project (D.W., D.Z., D.T., A.-C.M.). The aforementioned entities had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Kooreman, E.S.; van Houdt, P.J.; Nowee, M.E.; van Pelt, V.W.; Tijssen, R.H.; Paulson, E.S.; Gurney-Champion, O.J.; Wang, J.; Koetsveld, F.; van Buuren, L.D.; et al. Feasibility and accuracy of quantitative imaging on a 1.5 T MR-linear accelerator. *Radiother. Oncol.* 2019, 133, 156–162, doi:10.1016/j.radonc.2019.01.011.

2. Beyerdorff, D.; Taymoorian, K.; Knösel, T.; Schnorr, D.; Felix, R.; Hamm, B.; Bruhn, H. MRI of Prostate Cancer at 1.5 and 3.0 T: Comparison of Image Quality in Tumor Detection and Staging. *Am. J. Roentgenol.* 2005, 185, 1214–1220, doi:10.2214/ajr.04.1584.

3. Herk, M.V.; McWilliam, A.; Dubec, M.; Faiivre-Finn, C.; Choudhury, A. Magnetic Resonance Imaging-Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis, *Int. J. Radiat. Oncol. Biol. Phys.* 2018, 101, 1057–1060.

4. Hehakaya, C.; Zyp, J.R.V.D.V.V.; Lagendijk, J.J.W.; Moors, E.H.M. Problems and Promises of Introducing the Magnetic Resonance Imaging Linear Accelerator Into Routine Care: The Case of Prostate Cancer. *Front. Oncol.* 2020, 10, 1741, doi:10.3389/fonc.2020.01741.

5. Grégoire, V.; Guckenberger, M.; Haustermans, K.; Lagendijk, J.J.W.; Ménard, C.; Pötter, R.; Slotman, B.J.; Tanderrup, K.; Thorwarth, D.; Van Herk, M.; et al. Image guidance in radiation therapy for better cure of cancer. *Med. Oncol.* 2020, 14, 1470–1491, doi:10.1002/mp.12767.

6. Weinreb, J.C.; Barentsz, J.O.; Choyke, P.L.; Cornud, F.; Haider, M.A.; Macura, K.J.; Margolis, D.J.; Schnall, M.D.; Shtern, F.; Tempany, C.M.; et al. PI-RADS Prostate Imaging—Reporting and Data System: 2015, Version 2. *Eur. Urol.* 2016, 69, 16–40, doi:10.1016/j.euro.2015.08.052.

7. Wang, J.; Yung, J.; Kadbi, M.; Hwang, K.; Ding, Y.; Ibbott, G.S. Assessment of image quality and scatter and leakage radiation of an integrated MR-LINAC system. *Med. Phys.* 2018, 45, 1204–1209, doi:10.1002/mp.12767.

8. Stocker, D.; Manolius, A.; Becker, A.S.; Barth, B.K.; Nanz, D.; Klarhöfer, M.; Donati, O.F. Image Quality and Geometric Distortion of Modern Diffusion-Weighted Imaging Sequences in Magnetic Resonance Imaging of the Prostate. *Investig. Radiol.* 2018, 53, 200–206, doi:10.1097/rlt.0000000000000429.

9. Barth, B.K.; Cornelius, A.; Nanz, D.; Eberli, D.; Donati, O.F. Diffusion-weighted imaging of the prostate: Image quality and geometric distortion of readout-segmented versus selective-excitation accelerated acquisitions. *Investig. Radiol.* 2015, 50, 785–791.

10. Kromrey, J.D.; Rendina-Gobioff, G. An empirical comparison of regression analysis strategies with discrete ordinal variables. *Mult. Linear Regres. Vieuw.* 2002, 28, 30–43.

11. McCullagh, P. Regression Models for Ordinal Data. *J. R. Stat. Soc. Ser. B Stat. Methodol.* 1980, 42, 109–127, doi:10.1111/j.2517-6161.1980.tb01109.x.

12. Landis, J.R.; Koch, G.G. The Measurement of Observer Agreement for Categorical Data. *Biometrics* 1977, 33, 159–174, doi:10.2307/2529310.

13. Hallgren, K.A. Computing inter-rater reliability for observational data: An overview and tutorial. *Tutor. Quant. Methods Psychol.* 2012, 8, 23–24.
14. Keizer, D.D.M.; Kerkmeijer, L.; Willigenburg, T.; Van Lier, A.; Hartog, M.D.; Zyp, J.V.D.V.V.; Breugel, E.D.G.-V.; Raaymakers, B.; Lagendijk, J.; De Boer, J. Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac. Radiother. Oncol. 2020, 151, 88–94, doi:10.1016/j.radonc.2020.06.044.

15. Pommer, T.; Oh, J.H.; Rosenschöld, P.M.A.; Deasy, J.O. Simulating intrafraction prostate motion with a random walk model. Adv. Radiat. Oncol. 2017, 2, 429–436, doi:10.1016/j.adro.2017.03.005.

16. Donati, O.F.; Mazaheri, Y.; Afaq, A.; Vargas, H.A.; Zheng, J.; Moskowitz, C.S.; Hricak, H.; Akin, O. Prostate Cancer Aggressiveness: Assessment with Whole-Lesion Histogram Analysis of the Apparent Diffusion Coefficient. Radiology 2014, 271, 143–152, doi:10.1148/radiol.13130973.

17. Scheenen, T.W.; Rosenkrantz, A.B.; Haider, M.A.; Fütteterer, J.J. Multiparametric magnetic resonance imaging in prostate cancer management: Current status and future perspectives. Invest. Radiol. 2015, 50, 594–600.

18. Van Der Heide, U.A.; Houweling, A.C.; Groenendaal, G.; Beets-Tan, R.G.H.; Lambin, P. Functional MRI for radiotherapy dose painting. Magn. Reson. Imaging 2012, 30, 1216–1223, doi:10.1016/j.mri.2012.04.010.

19. Attenberger, U.I.; Rathmann, N.; Sertdemir, M.; Riffel, P.; Weidner, A.; Kannengiesser, S.; Morelli, J.N.; Schoenberg, S.O.; Hausmann, D. Small Field-of-view single-shot EPI-DWI of the prostate: Evaluation of spatially-tailored two-dimensional radiofrequency excitation pulses. Z. Med. Phys. 2016, 26, 168–176, doi:10.1016/j.zemedi.2015.06.013.

20. Torfeh, T.; Hammoud, R.; McGarry, M.; Al-Hammadi, N.; Perkins, G. Development and validation of a novel large field of view phantom and a software module for the quality assurance of geometric distortion in magnetic resonance imaging. Magn. Reson. Imaging 2015, 33, 939–949, doi:10.1016/j.mri.2015.04.003.

21. Fransson, A.; Andreo, P.; Pötter, R. Aspects of MR Image Distortions in Radiotherapy Treatment Planning. Strahlenther. Onkol. 2001, 177, 59–73, doi:10.1007/pl00002385.

22. Raaymakers, B.W.; Jürgenliemk-Schulz, L.M.; Bol, G.H.; Glitzner, M.; Kotte, A.N.T.J.; Van Asselen, B.; De Boer, J.C.J.; Bluemink, J.J.; Hackett, S.L.; A Moerland, M.; et al. First patients treated with a 1.5 T MRI-Linac: Clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. Phys. Med. Biol. 2017, 62, L41–L50, doi:10.1088/1361-6560/aa9517.

23. Das, I.J.; McGee, K.P.; Tyagi, N.; Wang, H. Role and future of MRI in radiation oncology. Br. J. Radiol. 2019, 92, 20180505, doi:10.1259/bjr.20180505.

24. Keesman, R.; Van De Lindt, T.N.; Juan-Cruz, C.; Wollenberg, W.V.D.; Van Der Bijl, E.; Nowee, M.E.; Sonke, J.; Van Der Heide, U.A.; Fast, M.F. Correcting geometric image distortions in slice-based 4D-MRI on the MR-linac. Med. Phys. 2019, 46, 3044–3054, doi:10.1002/mp.13602.

25. Ullrich, T.; Quentin, M.; Oelers, C.; Dietzel, F.; Sawicki, L.; Arsov, C.; Rabenalt, R.; Albers, P.; Antoch, G.; Blondin, D.; et al. Magnetic resonance imaging of the prostate at 1.5 versus 3.0 T: A prospective comparison study of image quality. Eur. J. Radiol. 2017, 90, 192–197, doi:10.1016/j.ejrad.2017.02.044.